Matthew Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2957468/publications.pdf

Version: 2024-02-01

233 papers 10,485 citations

50 h-index 94 g-index

241 all docs

241 docs citations

times ranked

241

8768 citing authors

#	Article	IF	Citations
1	Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin. Journal of Biological Chemistry, 2008, 283, 5866-5875.	1.6	1,136
2	Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone, 2012, 50, 209-217.	1.4	396
3	The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data. Journal of Oral and Maxillofacial Surgery, 2009, 67, 61-70.	0.5	353
4	Periosteum: biology, regulation, and response to osteoporosis therapies. Bone, 2004, 35, 1003-1012.	1.4	345
5	Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes. PLoS ONE, 2008, 3, e2942.	1.1	331
6	Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1146-55.	3.3	318
7	Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone, 2006, 39, 872-879.	1.4	226
8	A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. Journal of Clinical Investigation, 2004, 114, 1704-1713.	3.9	221
9	Cell autonomous requirement of connexin 43 for osteocyte survival: Consequences for endocortical resorption and periosteal bone formation. Journal of Bone and Mineral Research, 2012, 27, 374-389.	3.1	204
10	Mandible Matrix Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate Treatment. Journal of Oral and Maxillofacial Surgery, 2008, 66, 987-994.	0.5	196
11	Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporosis International, 2009, 20, 887-894.	1.3	185
12	PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. Journal of Bone and Mineral Research, 2011, 26, 1035-1046.	3.1	184
13	Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know. Bone, 2011, 49, 56-65.	1.4	182
14	Aging Reduces Skeletal Blood Flow, Endothelium-Dependent Vasodilation, and NO Bioavailability in Rats. Journal of Bone and Mineral Research, 2007, 22, 1280-1288.	3.1	144
15	Circulating \hat{l} ±Klotho influences phosphate handling by controlling FGF23 production. Journal of Clinical Investigation, 2012, 122, 4710-4715.	3.9	135
16	Exercise-induced changes in the cortical bone of growing mice are bone- and gender-specific. Bone, 2007, 40, 1120-1127.	1.4	128
17	Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis International, 2008, 19, 329-337.	1.3	126
18	Failure of mineralized collagen fibrils: Modeling the role of collagen cross-linking. Journal of Biomechanics, 2008, 41, 1427-1435.	0.9	121

#	Article	IF	CITATIONS
19	Three Years of Alendronate Treatment Results in Similar Levels of Vertebral Microdamage as After One Year of Treatment. Journal of Bone and Mineral Research, 2007, 22, 1759-1765.	3.1	120
20	Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing. Bone, 2013, 53, 301-305.	1.4	120
21	Site- and compartment-specific changes in bone with hindlimb unloading in mature adult rats. Bone, 2002, 31, 149-157.	1.4	114
22	Neonatal Iron Deficiency Causes Abnormal Phosphate Metabolism by Elevating FGF23 in Normal and ADHR Mice. Journal of Bone and Mineral Research, 2014, 29, 361-369.	3.1	109
23	Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone, 2010, 46, 666-672.	1.4	106
24	Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD). PLoS ONE, 2013, 8, e64558.	1.1	106
25	Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy. Journal of Bone and Mineral Research, 2015, 30, 499-509.	3.1	103
26	Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E765-E774.	1.8	100
27	Alendronate Reduces Bone Toughness of Ribs without Significantly Increasing Microdamage Accumulation in Dogs Following 3 Years of Daily Treatment. Calcified Tissue International, 2008, 82, 354-360.	1.5	95
28	Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. Journal of Bone and Mineral Research, 2016, 31, 1791-1802.	3.1	95
29	Raloxifene enhances vertebral mechanical properties independent of bone density. Bone, 2006, 39, 1130-1135.	1.4	92
30	Parathyroid Hormone Receptor Signaling Induces Bone Resorption in the Adult Skeleton by Directly Regulating the RANKL Gene in Osteocytes. Endocrinology, 2014, 155, 2797-2809.	1.4	92
31	Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthodontics and Craniofacial Research, 2009, 12, 221-228.	1.2	89
32	In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy. Matrix Biology, 2008, 27, 34-41.	1,5	77
33	Inhibition of Osteocyte Apoptosis Prevents the Increase in Osteocytic Receptor Activator of Nuclear Factor κB Ligand (RANKL) but Does Not Stop Bone Resorption or the Loss of Bone Induced by Unloading. Journal of Biological Chemistry, 2015, 290, 18934-18942.	1.6	74
34	Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. Journal of Bone and Mineral Research, 2010, 25, 98-105.	3.1	72
35	A Comparison of Calcium to Zoledronic Acid for Improvement of Cortical Bone in an Animal Model of CKD. Journal of Bone and Mineral Research, 2014, 29, 902-910.	3.1	72
36	Bone cell-independent benefits of raloxifene on the skeleton: A novel mechanism for improving bone material properties. Bone, 2014, 61, 191-200.	1.4	72

3

#	Article	IF	CITATIONS
37	Defective osteogenesis of the stromal stem cells predisposes CD18-null mice to osteoporosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14022-14027.	3.3	70
38	Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporosis International, 2008, 19, 1331-1341.	1.3	69
39	True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo. Journal of Bone and Mineral Research, 2015, 30, 1539-1550.	3.1	69
40	Mineralization, microdamage, and matrix: How bisphosphonates influence material properties of bone. BoneKEy Osteovision, 2007, 4, 49-60.	0.6	66
41	Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. PLoS ONE, 2016, 11, e0159411.	1.1	62
42	Hindlimb unloading has a greater effect on cortical compared with cancellous bone in mature female rats. Journal of Applied Physiology, 2003, 94, 642-650.	1.2	58
43	Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporosis International, 2011, 22, 693-702.	1.3	58
44	Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. Bone, 2015, 81, 352-363.	1.4	58
45	Conditional Deletion of Murine <i>Fgf23</i> : Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia. Journal of Bone and Mineral Research, 2016, 31, 1247-1257.	3.1	57
46	Human femoral neck has less cellular periosteum, and more mineralized periosteum, than femoral diaphyseal bone. Bone, 2005, 36, 311-316.	1.4	56
47	Bisphosphonates and Osteonecrosis of the Jaw: Moving from the Bedside to the Bench. Cells Tissues Organs, 2009, 189, 289-294.	1.3	56
48	Increased nitric oxide-mediated vasodilation of bone resistance arteries is associated with increased trabecular bone volume after endurance training in rats. Bone, 2010, 46, 813-819.	1.4	55
49	High Bone Mass in Mice Lacking Cx37 Because of Defective Osteoclast Differentiation. Journal of Biological Chemistry, 2014, 289, 8508-8520.	1.6	54
50	Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk. Journal of Orthopaedic Research, 2009, 27, 1288-1292.	1.2	52
51	Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. JCI Insight, 2019, 4, .	2.3	52
52	Antiremodeling Agents Influence Osteoblast Activity Differently in Modeling and Remodeling Sites of Canine Rib. Calcified Tissue International, 2006, 79, 255-261.	1.5	48
53	The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone, 2014, 64, 57-64.	1.4	48
54	Biglycan Deficiency Interferes With Ovariectomy-Induced Bone Loss. Journal of Bone and Mineral Research, 2003, 18, 2152-2158.	3.1	46

#	Article	IF	CITATIONS
55	Cx43 Overexpression in Osteocytes Prevents Osteocyte Apoptosis and Preserves Cortical Bone Quality in Aging Mice. JBMR Plus, 2018, 2, 206-216.	1.3	46
56	Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone, 2010, 46, 203-207.	1.4	45
57	The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific. Bone, 2006, 39, 106-116.	1.4	44
58	Raloxifene Enhances Material-Level Mechanical Properties of Femoral Cortical and Trabecular Bone. Endocrinology, 2007, 148, 3908-3913.	1.4	43
59	In vivo reference point indentation reveals positive effects of raloxifene on mechanical properties following 6months of treatment in skeletally mature beagle dogs. Bone, 2013, 56, 449-453.	1.4	43
60	Bisphosphonates do not alter the rate of secondary mineralization. Bone, 2011, 49, 701-705.	1.4	42
61	The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology / the Society of the Nippon Dental University, 2011, 99, 8-17.	0.9	42
62	Resorption Controls Bone Anabolism Driven by Parathyroid Hormone (PTH) Receptor Signaling in Osteocytes. Journal of Biological Chemistry, 2013, 288, 29809-29820.	1.6	41
63	Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporosis International, 2008, 19, 95-99.	1.3	40
64	PTHrP-Derived Peptides Restore Bone Mass and Strength in Diabetic Mice: Additive Effect of Mechanical Loading. Journal of Bone and Mineral Research, 2017, 32, 486-497.	3.1	40
65	Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease. PLoS ONE, 2014, 9, e99262.	1.1	40
66	Erythropoietin and a hypoxiaâ€inducible factor prolyl hydroxylase inhibitor (HIFâ€PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiological Reports, 2020, 8, e14434.	0.7	39
67	Biglycan-Deficient Mice Have Delayed Osteogenesis after Marrow Ablation. Calcified Tissue International, 2003, 72, 577-582.	1.5	37
68	Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporosis International, 2013, 24, 1471-1481.	1.3	37
69	Heritability of lumbar trabecular bone mechanical properties in baboons. Bone, 2010, 46, 835-840.	1.4	36
70	Skeletal Microdamage: Less About Biomechanics and More About Remodeling. Clinical Reviews in Bone and Mineral Metabolism, 2008, 6, 24-30.	1.3	35
71	Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1371-1378.	1.5	35
72	Bisphosphonate Binding Affinity Affects Drug Distribution in Both Intracortical and Trabecular Bone of Rabbits. Calcified Tissue International, 2012, 90, 202-210.	1.5	35

#	Article	IF	Citations
73	Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease. Osteoporosis International, 2015, 26, 977-985.	1.3	35
74	Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible. Orthodontics and Craniofacial Research, 2010, 13, 214-222.	1.2	34
75	Pathogenesis of Arrhythmias in a Model of CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 2812-2821.	3.0	34
76	Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs. Bone, 2015, 71, 58-62.	1.4	34
77	Functional recovery of the plantarflexor muscle group after hindlimb unloading in the rat. European Journal of Applied Physiology, 2004, 93, 130-138.	1.2	33
78	Morphological Assessment of Basic Multicellular Unit Resorption Parameters in Dogs Shows Additional Mechanisms of Bisphosphonate Effects on Bone. Calcified Tissue International, 2010, 86, 67-71.	1.5	33
79	Defective cancellous bone structure and abnormal response to PTH in cortical bone of mice lacking Cx43 cytoplasmic C-terminus domain. Bone, 2015, 81, 632-643.	1.4	33
80	Prenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry. ELife, 2021, 10, .	2.8	32
81	Food restriction and simulated microgravity: effects on bone and serum leptin. Journal of Applied Physiology, 2008, 104, 1086-1093.	1.2	31
82	Methodological assessment of acidâ€etching for visualizing the osteocyte lacunarâ€canalicular networks using scanning electron microscopy. Microscopy Research and Technique, 2010, 73, 182-186.	1.2	31
83	Absence of Exposed Bone Following Dental Extraction in Beagle Dogs Treated With 9ÂMonths of High-Dose Zoledronic Acid Combined With Dexamethasone. Journal of Oral and Maxillofacial Surgery, 2013, 71, 1017-1026.	0.5	31
84	Effect of Advanced Glycation Endâ€Products (AGE) Lowering Drug ALTâ€₹11 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKDâ€MBD. Journal of Bone and Mineral Research, 2020, 35, 608-617.	3.1	31
85	Aging and Estrogen Status: A Possible Endothelium-Dependent Vascular Coupling Mechanism in Bone Remodeling. PLoS ONE, 2012, 7, e48564.	1.1	31
86	Differential bone and muscle recovery following hindlimb unloading in skeletally mature male rats. Journal of Musculoskeletal Neuronal Interactions, 2006, 6, 217-25.	0.1	31
87	Identification of material parameters based on Mohr–Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone. Bone, 2008, 43, 775-780.	1.4	30
88	<i>In vivo</i> effects of zoledronic acid on oral mucosal epithelial cells. Oral Diseases, 2011, 17, 291-297.	1.5	29
89	Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone. Bone, 2015, 73, 8-15.	1.4	29
90	Inhibition of CaMKK2 Enhances Fracture Healing by Stimulating Indian Hedgehog Signaling and Accelerating Endochondral Ossification. Journal of Bone and Mineral Research, 2018, 33, 930-944.	3.1	29

#	Article	IF	Citations
91	Higher Bone Matrix Density Exists in Only a Subset of Patients With Bisphosphonate-Related Osteonecrosis of the Jaw. Journal of Oral and Maxillofacial Surgery, 2009, 67, 1373-1377.	0.5	28
92	Medication-Related Osteonecrosis of the Jaw. Oral and Maxillofacial Surgery Clinics of North America, 2015, 27, 497-508.	0.4	28
93	Animal models of osteonecrosis of the jaw. Journal of Musculoskeletal Neuronal Interactions, 2007, 7, 358-60.	0.1	28
94	One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation. Bone, 2010, 47, 241-247.	1.4	27
95	A Review of Pharmaceutical Agents and Oral Bone Health: How Osteonecrosis of the Jaw Has Affected the Field. International Journal of Oral and Maxillofacial Implants, 2014, 29, e45-e57.	0.6	27
96	Effects of skeletal unloading on the vasomotor properties of the rat femur principal nutrient artery. Journal of Applied Physiology, 2015, 118, 980-988.	1.2	27
97	Time course of rapid bone loss and cortical porosity formation observed by longitudinal νCT in a rat model of CKD. Bone, 2019, 125, 16-24.	1.4	27
98	Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice. Bone, 2019, 124, 89-102.	1.4	26
99	Increased strontium uptake in trabecular bone of ovariectomized calcium-deficient rats treated with strontium ranelate or strontium chloride. Journal of Synchrotron Radiation, 2011, 18, 835-841.	1.0	24
100	The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts. Bone, 2014, 60, 235-245.	1.4	24
101	Even with rehydration, preservation in ethanol influences the mechanical properties of bone and how bone responds to experimental manipulation. Bone, 2017, 97, 49-53.	1.4	24
102	Partial Weight Bearing Does Not Prevent Musculoskeletal Losses Associated with Disuse. Medicine and Science in Sports and Exercise, 2013, 45, 2052-2060.	0.2	23
103	Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone, 2015, 77, 50-56.	1.4	23
104	Simulating the Lunar Environment: Partial Weightbearing and High-LET Radiation-Induce Bone Loss and Increase Sclerostin-Positive Osteocytes. Radiation Research, 2016, 186, 254-263.	0.7	23
105	Beta-1 Adrenergic Agonist Treatment Mitigates Negative Changes in Cancellous Bone Microarchitecture and Inhibits Osteocyte Apoptosis during Disuse. PLoS ONE, 2014, 9, e106904.	1.1	22
106	Genetic Rescue of Glycosylation-deficient Fgf23 in the Galnt3 Knockout Mouse. Endocrinology, 2014, 155, 3891-3898.	1.4	22
107	Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta. Matrix Biology, 2016, 52-54, 19-28.	1.5	22
108	Effects of eccentric exercise training on cortical bone and muscle strength in the estrogen-deficient mouse. Journal of Applied Physiology, 2005, 98, 1674-1681.	1.2	21

#	Article	lF	Citations
109	Development of an in vivo rabbit ulnar loading model. Bone, 2015, 75, 55-61.	1.4	21
110	A computational assessment of the independent contribution of changes in canine trabecular bone volume fraction and microarchitecture to increased bone strength with suppression of bone turnover. Journal of Biomechanics, 2007, 40, 3424-3431.	0.9	20
111	Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate. Bone, 2011, 49, 128-132.	1.4	20
112	Intracortical Bone Remodeling Variation Shows Strong Genetic Effects. Calcified Tissue International, 2013, 93, 472-480.	1.5	20
113	Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties. Current Osteoporosis Reports, 2018, 16, 198-204.	1.5	20
114	Orthodontic mini-implant diameter does not affect in-situ linear microcrack generation in the mandible or the maxilla. American Journal of Orthodontics and Dentofacial Orthopedics, 2012, 142, 768-773.	0.8	19
115	In Vivo UTE-MRI Reveals Positive Effects of Raloxifene on Skeletal-Bound Water in Skeletally Mature Beagle Dogs. Journal of Bone and Mineral Research, 2015, 30, 1441-1444.	3.1	19
116	Structural features underlying raloxifene's biophysical interaction with bone matrix. Bioorganic and Medicinal Chemistry, 2016, 24, 759-767.	1.4	19
117	Raloxifene improves skeletal properties in an animalÂmodel of cystic chronic kidney disease. Kidney International, 2016, 89, 95-104.	2.6	19
118	Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice. PLoS ONE, 2021, 16, e0250438.	1.1	19
119	Age and sex effects on FGF23-mediated response to mild phosphate challenge. Bone, 2021, 146, 115885.	1.4	19
120	Bone hydration: How we can evaluate it, what can it tell us, and is it an effective therapeutic target?. Bone Reports, 2022, 16, 101161.	0.2	19
121	Effects of spaceflight on the murine mandible: Possible factors mediating skeletal changes in non-weight bearing bones of the head. Bone, 2016, 83, 156-161.	1.4	18
122	Incorporating tissue anisotropy and heterogeneity in finite element models of trabecular bone altered predicted local stress distributions. Biomechanics and Modeling in Mechanobiology, 2018, 17, 605-614.	1.4	18
123	Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD. Calcified Tissue International, 2020, 106, 392-400.	1.5	18
124	Low Bone Turnover in Chronic Kidney Disease Is Associated with Decreased VEGF-A Expression and Osteoblast Differentiation. American Journal of Nephrology, 2015, 41, 464-473.	1.4	17
125	Reference point indentation is insufficient for detecting alterations in traditional mechanical properties of bone under common experimental conditions. Bone, 2016, 87, 97-101.	1.4	17
126	Dietary Phosphate Restriction Normalizes Biochemical and Skeletal Abnormalities in a Murine Model of Tumoral Calcinosis. Endocrinology, 2011, 152, 4504-4513.	1.4	16

#	Article	IF	CITATIONS
127	Microcrack density and nanomechanical properties in the subchondral region of the immature piglet femoral head following ischemic osteonecrosis. Bone, 2013, 52, 632-639.	1.4	16
128	Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease. Nephrology Dialysis Transplantation, 2015, 31, gfv352.	0.4	16
129	Exposure to Low-Dose X-Ray Radiation Alters Bone Progenitor Cells and Bone Microarchitecture. Radiation Research, 2017, 188, 433-442.	0.7	16
130	Voluntary Chronic Heavy Alcohol Consumption in Male Rhesus Macaques Suppresses Cancellous Bone Formation and Increases Bone Marrow Adiposity. Alcoholism: Clinical and Experimental Research, 2019, 43, 2494-2503.	1.4	16
131	Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone. Bone, 2019, 127, 199-206.	1.4	16
132	The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model. Journal of Bone and Mineral Research, 2020, 36, 1117-1130.	3.1	16
133	Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone, 2004, 35, 134-143.	1.4	14
134	Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. Osteoporosis International, 2009, 20, 647-652.	1.3	14
135	Preclinical Models for Skeletal Research: How Commonly Used Species Mimic (or Don't) Aspects of Human Bone. Toxicologic Pathology, 2017, 45, 851-854.	0.9	14
136	Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy/+ rats. Scientific Reports, 2019, 9, 7936.	1.6	14
137	Mechanics of linear microcracking in trabecular bone. Journal of Biomechanics, 2019, 83, 34-42.	0.9	14
138	Muscle contraction induces osteogenic levels of cortical bone strain despite muscle weakness in a mouse model of Osteogenesis Imperfecta. Bone, 2020, 132, 115061.	1.4	14
139	Animal Models of Osteonecrosis. Clinical Reviews in Bone and Mineral Metabolism, 2011, 9, 63-80.	1.3	13
140	Variability of in vivo reference point indentation in skeletally mature inbred rats. Journal of Biomechanics, 2014, 47, 2504-2507.	0.9	13
141	Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes. Osteoporosis International, 2016, 27, 3637-3643.	1.3	13
142	Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease. Bone, 2021, 143, 115632.	1.4	13
143	Low Bone Turnover and Microdamage? How and Where to Assess It?. Journal of Bone and Mineral Research, 2008, 23, 1150-1151.	3.1	12
144	A novel approach to evaluate the effect of medicaments used in endodontic regeneration on root canal surface indentation. Clinical Oral Investigations, 2014, 18, 1569-1575.	1.4	12

#	Article	IF	Citations
145	Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis. Molecular Endocrinology, 2015, 29, 1269-1285.	3.7	12
146	Reversal of loss of bone mass in old mice treated with mefloquine. Bone, 2018, 114, 22-31.	1.4	12
147	Age- and sex-dependent role of osteocytic pannexin1 on bone and muscle mass and strength. Scientific Reports, 2019, 9, 13903.	1.6	12
148	Loss of <i>Nmp4</i> optimizes osteogenic metabolism and secretion to enhance bone quality. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E749-E772.	1.8	12
149	Parathyroid Hormone and Bone Biomechanics. Clinical Reviews in Bone and Mineral Metabolism, 2006, 4, 259-268.	1.3	11
150	Calculating clinically relevant drug doses to use in animal studies. Osteoporosis International, 2008, 19, 1815-1817.	1.3	11
151	Lack of Correlation Between Duration of Osteonecrosis of the Jaw and Sequestra Tissue Morphology: What It Tells Us About the Condition and What It Means for Future Studies. Journal of Oral and Maxillofacial Surgery, 2010, 68, 2730-2734.	0.5	11
152	Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels. Bone, 2021, 148, 115963.	1.4	11
153	Adverse Mandibular Bone Effects Associated with Kidney Disease Are Only Partially Corrected with Bisphosphonate and/or Calcium Treatment. American Journal of Nephrology, 2013, 38, 458-464.	1.4	10
154	Osteocytic miR21 deficiency improves bone strength independent of sex despite having sex divergent effects on osteocyte viability and bone turnover. FEBS Journal, 2020, 287, 941-963.	2.2	10
155	Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage. Journal of Biomechanics, 2009, 42, 938-944.	0.9	9
156	What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease. Current Osteoporosis Reports, 2017, 15, 171-177.	1.5	9
157	Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate. Calcified Tissue International, 2017, 101, 75-81.	1.5	9
158	Rad GTPase is essential for the regulation of bone density and bone marrow adipose tissue in mice. Bone, 2017, 103, 270-280.	1.4	9
159	Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism. Endocrinology, 2017, 158, 2722-2740.	1.4	9
160	Voluntary Wheel Running Has Beneficial Effects in a Rat Model of CKD-Mineral Bone Disorder (CKD-MBD). Journal of the American Society of Nephrology: JASN, 2019, 30, 1898-1909.	3.0	9
161	In vivo reference point indentation measurement variability in skeletally mature inbred mice. BoneKEy Reports, 2015, 4, 712.	2.7	9
162	Bisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependent. Journal of Orthopaedic Research, 2013, 31, 1317-1322.	1.2	8

#	Article	IF	CITATIONS
163	Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease. Osteoporosis International, 2018, 29, 2139-2146.	1.3	8
164	$6\hat{a}$ €²-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding. Bone Reports, 2020, 12, 100246.	0.2	8
165	The Effect of Single Versus Group $\langle scp \rangle \hat{l}^{1}/4CT \langle scp \rangle$ on the Detection of Trabecular and Cortical Disease Phenotypes in Mouse Bones. JBMR Plus, 2021, 5, e10473.	1.3	8
166	Systemic inhibition or global deletion of CaMKK2 protects against post-traumatic osteoarthritis. Osteoarthritis and Cartilage, 2022, 30, 124-136.	0.6	8
167	Skin wound trauma, following high-dose radiation exposure, amplifies and prolongs skeletal tissue loss. Bone, 2015, 81, 487-494.	1.4	7
168	Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements. Journal of Cardiovascular Electrophysiology, 2015, 26, 671-677.	0.8	7
169	Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease. American Journal of Nephrology, 2016, 43, 20-31.	1.4	7
170	Assessment of regional bone tissue perfusion in rats using fluorescent microspheres. Bone Reports, 2017, 6, 140-144.	0.2	7
171	Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease. Bone, 2022, 157, 116340.	1.4	7
172	Osteonecrosis of the jaw: Recent clinical and preclinical advances. IBMS BoneKEy, 2011, 8, 141-153.	0.1	6
173	Assessing the inter- and intra-animal variability of in vivo OsteoProbe skeletal measures in untreated dogs. Bone Reports, 2016, 5, 192-198.	0.2	6
174	Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone, 2019, 127, 419-426.	1.4	6
175	N-acetylcysteine (NAC), an anti-oxidant, does not improve bone mechanical properties in a rat model of progressive chronic kidney disease-mineral bone disorder. PLoS ONE, 2020, 15, e0230379.	1.1	6
176	Surface-specific Bone Formation Effects of Osteoporosis Pharmacological Treatments. Clinical Reviews in Bone and Mineral Metabolism, 2008, 6, 62-69.	1.3	5
177	Studying the role of microcracks in the pathophysiology of BRONJ. Clinical Oral Investigations, 2009, 13, 481-482.	1.4	5
178	Can deterministic mechanical size effects contribute to fracture and microdamage accumulation in trabecular bone?. Journal of Theoretical Biology, 2010, 265, 202-210.	0.8	5
179	Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1Âyear. Osteoporosis International, 2012, 23, 2313-2320.	1.3	5
180	Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness. Bone, 2013, 56, 199-203.	1.4	5

#	Article	IF	CITATIONS
181	Positive impact of low-dose, high-energy radiation on bone in partial- and/or full-weightbearing mice. Npj Microgravity, 2019, 5, 13.	1.9	5
182	Blueberry Polyphenols do not Improve Bone Mineral Density or Mechanical Properties in Ovariectomized Rats. Calcified Tissue International, 2022, 110, 260-265.	1.5	5
183	Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model. PLoS ONE, 2017, 12, e0181750.	1.1	5
184	Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrology Dialysis Transplantation, 2022, 37, 1857-1867.	0.4	5
185	Effects of suppression of bone turnover on cortical and trabecular load sharing in the canine vertebral body. Journal of Biomechanics, 2009, 42, 517-523.	0.9	4
186	Foreword: Calcified Tissue International and Musculoskeletal Research Special Issue. Calcified Tissue International, 2015, 97, 199-200.	1.5	4
187	The fracture toughness of small animal cortical bone measured using arc-shaped tension specimens: Effects of bisphosphonate and deproteinization treatments. Bone, 2017, 105, 67-74.	1.4	4
188	Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study. Osteoporosis International, 2019, 30, 1693-1698.	1.3	4
189	Adverse Effects of Autoclaved Diets on the Progression of Chronic Kidney Disease and Chronic Kidney Disease-Mineral Bone Disorder in Rats. American Journal of Nephrology, 2020, 51, 381-389.	1.4	4
190	Iron deficiency and high-intensity running interval training do not impact femoral or tibial bone in young female rats. British Journal of Nutrition, 2022, 128, 1518-1525.	1.2	4
191	Skeletal vascular perfusion is altered in chronic kidney disease. Bone Reports, 2018, 8, 215-220.	0.2	3
192	Daily Acute Bouts of Weight-bearing During Hindlimb Unloading Mitigate Disuse-Induced Deficits in Cancellous Bone. Gravitational and Space Research: Publication of the American Society for Gravitational and Space Research, 2018, 6, 2-11.	0.3	3
193	Response to Comments on "True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo― Journal of Bone and Mineral Research, 2015, 30, 2327-2327.	3.1	2
194	Response to Courtney et al Bone, 2016, 89, 77-79.	1.4	2
195	Effects of daily restraint with and without injections on skeletal properties in C57BL/6NHsd mice. Lab Animal, 2017, 46, 299-301.	0.2	2
196	Carbon Monoxide and Exercise Prevents Dietâ€Induced Obesity and Metabolic Dysregulation Without Affecting Bone. Obesity, 2020, 28, 924-931.	1.5	2
197	Effects of anti-resorptive treatment on the material properties of individual canine trabeculae in cyclic tensile tests. Bone, 2021, 150, 115995.	1.4	2
198	Modeling of Bone Failure by Cohesive Zone Models. , 2013, , 217-230.		2

#	Article	IF	CITATIONS
199	The Effect of Age on Material Properties. , 2010, , 221-232.		2
200	<scp>Nonâ€Additive</scp> Effects of Combined <scp>NOX1</scp> /4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Diseaseâ€Mineral and Bone Disorder (<scp>CKDâ€MBD</scp>). JBMR Plus, 2022, 6, e10600.	1.3	2
201	Segregating the effects of ferric citrateâ€mediated iron utilization and FGF23 in a mouse model of CKD. Physiological Reports, 2022, 10, .	0.7	2
202	Does rat + bisphosphonate + exposed bone = an animal model of ONJ?. IBMS BoneKEy, 2009, 6, 227-231.	0.1	1
203	Letter to the Editor. Journal of Oral and Maxillofacial Surgery, 2013, 71, 1308.	0.5	1
204	Anatomy and Structural Considerations. , 2020, , 218-232.		1
205	Kidney Disease and Bone: Changing the Way We Look at Skeletal Health. Current Osteoporosis Reports, 2020, 18, 242-246.	1.5	1
206	NMUR1 in the NMU-Mediated Regulation of Bone Remodeling. Life, 2021, 11, 1028.	1.1	1
207	Exercise Can Reverse the Phenotype of Biglycan Deficient Mice. , 2003, , .		1
208	Animal Models of Medication-Related Osteonecrosis of the Jaw. , 2015, , 155-167.		1
209	The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype. Bone, 2022, 154, 116228.	1.4	1
210	Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease. Bone Reports, 2022, 16, 101174.	0.2	1
211	Femoral Skeletal Perfusion is Reduced in Male Mice with Type 1 Diabetes. Calcified Tissue International, 2022, 111, 323-330.	1.5	1
212	Nanometer resolution hard X-ray microscopy of bone and mineralized tissue. , 2007, , .		0
213	Reply to: Fatigue in bone: A novel phenomenon attributable to bisphosphonate use. Bone, 2010, 47, 455.	1.4	0
214	Bisphosphonates and PTH for Preventing Fractures. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2012, , 151-176.	0.7	0
215	Forward: A Fresh Look at Measuring and Altering Bone Quality. Clinical Reviews in Bone and Mineral Metabolism, 2016, 14, 131-132.	1.3	0
216	2018â€"Changing Times for CRBM. Clinical Reviews in Bone and Mineral Metabolism, 2018, 16, 1-2.	1.3	0

#	Article	IF	Citations
217	38460 Independent Investigator Incubator (I3) yields external funding within three years for the majority of junior faculty. Journal of Clinical and Translational Science, 2021, 5, 64-64.	0.3	O
218	11039 Indiana CTSI High-School STEM Summer Research Program: Future opportunities from a 2020 virtual program. Journal of Clinical and Translational Science, 2021, 5, 63-63.	0.3	0
219	Exerciseâ€induced increases in trabecular bone volume are associated with increased nitric oxideâ€mediated vasodilation in osseous vasculature of young and old rats. FASEB Journal, 2009, 23, 955.21.	0.2	0
220	Bisphosphonates and bone: understanding biological mechanisms using morphological techniques. FASEB Journal, 2009, 23, 74.4.	0.2	0
221	Weightbearing In Simulated 1/6th and 1/3rd Gravity Does Not Prevent Cancellous Bone Loss. FASEB Journal, 2010, 24, 616.7.	0.2	0
222	Habitual calcium intake and vitamin D status during adulthood through estrogen deficiency have few interactions on calcium kinetics and bone. FASEB Journal, 2012, 26, 244.3.	0.2	0
223	Reducing parathyroid hormone is essential for correcting cortical bone deficiencies associated with chronic kidney disease. FASEB Journal, 2013, 27, 967.10.	0.2	0
224	In vivo assessment of skeletal biomechanical properties reveals beneficial effects of combination antiâ€remodeling drug treatment. FASEB Journal, 2013, 27, lb32.	0.2	0
225	Treating Bone Quality in Chronic Kidney Disease. FASEB Journal, 2015, 29, 702.1.	0.2	0
226	Mechanisms need not be molecular ―tissueâ€level mechanisms for drugâ€induced changes to bone mechanical properties. FASEB Journal, 2015, 29, 12.4.	0.2	0
227	In Vivo Reference Point Indentation Variability in Skeletally Mature Inbred Mice. FASEB Journal, 2015, 29, 698.1.	0.2	0
228	The beneficial effects of lowâ€dose carbon monoxide and moderate intensity endurance exercise on metabolic and skeletal properties. FASEB Journal, 2018, 32, 719.9.	0.2	0
229	The Role of Microdamage in Bone Mechanics and Osteoporotic Fractures. , 2022, , 209-220.		0
230	Title is missing!. , 2020, 15, e0230379.		0
231	Title is missing!. , 2020, 15, e0230379.		0
232	Title is missing!. , 2020, 15, e0230379.		0
233	Title is missing!. , 2020, 15, e0230379.		0